TP53 and colorectal cancer: β-sitosterol reverses oxaliplatin resistance in drug-resistant colorectal cancer cells by inhibiting the p53-MDM2 interaction in colorectal cancer by activating p53, leading to increased p53 translocation to the nucleus and the NF-κB pathway, which in turn inhibits the breast cancer resistance protein (BCRP) (Wang Z et al., 2020).